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Abstract
Objectives The aim of this study was to develop mucoadhesive oral strips using
hot-melt extrusion as a continuous manufacturing process.
Methods Powder4 blends of ketoconazole, a water-insoluble drug – either hydrox-
ypropyl methylcellulose (HPMC) or soluplus (SOL), sorbitol (SRB) and magne-
sium aluminometasilicate (MAS) were extruded to manufacture thin strips with
0.5-mm thickness. The presence of the inorganic metasilicate facilitated smooth
processing of the extruded strips as it worked as an absorbent directly impacting
on the extensive mixing of the drug/excipients inside the extruder barrel.
Key ﬁndings The use of MAS also favoured the rapid hydration, swelling and
eventual disintegration of the strips. Differential scanning calorimetry and trans-
mission X-ray diffraction analysis revealed the existence of the amorphous drug
within the extruded strips. Scanning electron microscopy and energy dispersive
X-ray undertaken on the formulations showed a homogeneous drug distribution
within the extruded strips.
Conclusion The strips produced via continuous hot-melt extrusion processing
showed signiﬁcantly faster release of ketoconazole compared to the bulk drug
substance.
Introduction
‘Strips’ (commonly referred to as ﬁlms) can be deﬁned
as thin sheets containing one or more polymers with or
without a plasticizer and can effectively be used as a drug
delivery system. While, the solvent – casting approach –
currently a pharmaceutically adopted process, allows better
uniformity, ﬂexibility and adjustable thickness, this
approach is limited by low drug loading, high costs and
time consumption for development.[1–3] Furthermore, the
excessive use of various solvents to dissolve insoluble poly-
mer or drug makes the solvent casting method questionable
from the regulatory viewpoint. Moreover, the hazardous
nature of most organic solvents and the residual solvents
[4–7] left in the ﬁlms may create signiﬁcant environmental
and health concerns. Therefore, there is increasing current
interest in alternative technologies in the pharmaceutical
industry to overcome some or all of the challenges
currently associated with solvent ﬁlm casting.
Hot-melt extrusion (HME) has been successfully
exploited for the manufacturing of oral thin ﬁlms or strips
due to its unique advantages.[8] HME is a solvent-free green
technology, easy to scale up and operates in a continuous
mode.[9–11] Another key advantage of HME is that robust
extruded ﬁlms/strips can be obtained in a single processing
step making the process economically viable. In a HME
process, melt extruded strips are produced via feeding the
blends of appropriate amounts of the relevant polymer(s),
drug, plasticiser and other excipients into the preheated
extruder barrel and conveying them with rotating screws
into homogenous sheets. Other excipients can be added to
enhance functionally important properties of the strips
such as bioadhesive agents to ensure that the ﬁlm adheres
to the oral mucosal surface for the appropriate time periods
to allow drug absorption.[8]
Various studies have been reported on the manufacture
of oral strips using HME. Tumuluri et al. and Prodduturi
et al. conducted extensive research on the use of HME for
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the manufacture of mucoadhesive buccal ﬁlms with differ-
ent matrix formers and additives.[12,13] In an early investi-
gation, the group found that the addition of plasticizers,
such as triethyl citrate, PEG 2000/8000, or acetyltributyl
citrate, allowed the manufacture of thin, ﬂexible and stable
ﬁlms when hydroxypropyl cellulose (HPC) was used as ﬁlm
forming polymer.[13] It was shown that the increase in the
molecular weight of HPC decreased the release of drugs
from extruded ﬁlms, which resulted in dissolution proﬁles
exhibiting zero-order drug release.[14,15]
Ketoconazole (KTZ) is an antifungal agent mainly used
for the treatment of local and systemic fungal infections in
various forms (e.g. oral tablets, topical creams, gels, aero-
sols, suspensions and shampoos). Due to its very poor
water solubility (17 lg/ml) and high permeability, KTZ is
classiﬁed as biopharmaceutics classiﬁcation system (BCS)
class II drug. Increasing the solubility of KTZ is a challeng-
ing task as it signiﬁcantly reduces the oral bioavailability of
the drug and thus the therapeutic effectiveness.[15] We
report, to the best of our knowledge, a new case to manu-
facture KTZ-based oral strips using inorganic excipients via
a continuous HME processing and the physicochemical
characterization of the developed strips where the novelty
of this article lies. The distribution of the drug particles on
the surface of the manufactured oral strips is also investi-
gated as well as the strips’ hydration/swelling, mucoadhe-
sion and mechanical properties.
Materials and Methods
Materials
Ketoconazole was purchased from Sigma-Aldrich (Gilling-
ham, UK). Hydroxypropyl methylcellulose K4 (HPMC)
and magnesium aluminometasilicate (Neusilin, MAS) were
kindly donated by Colorcon (Dartford, UK) and Fuji
Chemical Industry Co., Ltd. (Japan), respectively. Soluplus
(SOL) was kindly donated by BASF, Germany. Sorbitol and
polyethylene glycol 2000 (PEG) were provided by Roquette
(Lestrem, France) and Fluka (Gillingham, UK). Sodium
CMC was purchased from Sigma-Aldrich (Gillingham,
UK). The HPLC solvents were of analytical grade and pur-
chased from Fisher Chemicals (Loughborough, UK). All
materials were used as received.
Drug/polymer miscibility determination
The drug/polymer miscibility was determined by calculat-
ing Hansen solubility parameters (d) of both the drug and
polymers. By considering the chemical structure and the
orientations of all drug/polymers, the solubility parameters
were calculated by using the following equation, which is
known as Hoftyzer and Van Krevelen method:[16,17]
d ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
d2d þ d
2
p þ d
2
h
q
ð1Þ
Here,
dd ¼
RFdi
Vt
; dp ¼
ffiffiffiffiffiffiffiffiffi
RF2pi
q
Vt
; dp ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðREhi=ViÞ
p
where d is total solubility parameter calculated, Fdi is the
constant (molar attraction) due to molar dispersion forces,
F2pi is the constant (molar attraction) due to molar polar-
ization forces, Ehi is the hydrogen bonding energy, and Vi is
the group contribution to molar volume.
Preparation of formulation blends and
continuous HME processing
Ketoconazole formulations with HPMC and SOL as poly-
meric matrices and a drug loading ranging from 5 to 20%
(w/w) (Table 1) were thoroughly mixed in a Turbula TF2
mixer (Basel, Switzerland) mixer in 100 g batches for 10 min
each, before the extrusion process. About 1 g of powdered
samples from each batch (physical mixture) was preserved in
an air-tight glass vial for further analyses. Appropriately
weighted MAS, SRB and PEG were added to the Turbula
mixtures before the extrusion process. Extrusion of all for-
mulations was performed using a EuroLab 16 twin-screw
extruder (Thermo Fisher, Germany) equipped with a spe-
cially designed die to produce strips of 0.5-mm thickness and
temperature proﬁle at 50 °C/130 °C/140 °C/140 °C/140
°C/140 °C/140 °C/140 °C/140 °C/140 °C (from feeding
zone ? Die) temperature proﬁles. The screw speed main-
tained for all extrusions was 100 rpm. The extrudates were
fed continuously to a PFL-590 cutting machine (Kunshan
Pingfenglong Trade Co., Ltd, China) and cut into strips of
1 cm 9 5 cm (100 mg of KTZ in each strip).
Hydration and swelling studies
The hydration (swelling) proﬁles of the strips were deter-
mined using a modiﬁed method from that previously
Table 1 Formulation composition of the KTZ oral strips (w/w %)
Excipients F1 F2 F3 F4
HPMC
(Blank)
SOL
(Blank) Control
KTZ 20 15 20 15 – – –
HPMC 30 40 – – 50 – 60
SOL – – 30 40 – 50 –
MAS 10 10 10 10 10 10 –
PEG 20 15 20 15 20 20 20
SRB 10 10 10 10 10 10 10
NaCMC 10 10 10 10 10 10 10
KTZ, Ketoconazole; MAS, magnesium aluminometasilicate; PEG, poly-
ethylene glycol; SRB, sorbitol; HPMC, hydroxypropyl methylcellulose;
SOL, soluplus.
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described.[18] Brieﬂy, the strips were initially weighed and
recorded as Wi and then placed in a Petri dish containing
10 ml of 0.1 M PBS, pH 6.8  0.1, at 37 °C. At predeter-
mined time intervals (20 min), the liquid medium was
removed, the strips blotted carefully with tissue paper to
remove the surface-adhered liquid droplets and reweighed
on an electronic balance and recorded as Wt. Fresh medium
(10 ml) was then added to the already swollen strip, and
the process continued till maximum swelling was obtained
(up to 80 min). The percentage of water uptake was
calculated as follows:
Swelling Capacity ð%Þ ¼ 100
Wt Wi
Wi
ð2Þ
where, Wt is the weight of the hydrated wafer at time t, and
Wi is the initial weight of wafer.
In-vitro mucoadhesion studies
Mucoadhesive measurements were performed on the strips
using a previously reported method.[19] The strips
(1 cm 9 2 cm dimensions) were attached to a 75-mm
diameter-adhesive rig probe with a double-sided adhesive
tape on a TA.HD.plus Texture Analyser (Stable Micro Sys-
tems, Surrey, UK) ﬁtted with a 5-kg load cell in tension
mode. The model mucosal surface was gelatin gel which
was allowed to set in a Petri dish (diameter 88 mm). The
set gelatin gel was equilibrated with 2% mucin solution
(adjusted to pH of 6.8  0.1) for 1 min and placed on the
instrument platform. The probe, lined with the strip was
lowered towards the gelatin surface at pretest speed of
0.5 mm/s, test speed of 0.5 mm/s and post speed of
1.00 mm/s. The maximum force required to detach the
strip on the upper probe from the mucosal surface, known
as the peak adhesion force (PAF), was determined. The area
under the curve (AUC) representing total work of adhesion
(TWA) of the wafers was estimated from the force–distance
plot while the cohesiveness of the samples was determined
by the distance of travel.
Scanning electron microscopy (SEM)/energy
dispersive X-ray (EDS) analysis
The spatial distribution of discreet chemical phases was
evaluated using a cold cathode ﬁeld emission gun scanning
electron microscope (Hitachi SU8030 FEG-SEM, Japan)
and Thermo Noran (USA) EDS system with 30 mm2 win-
dow Ultra Dry detector and Noran 7 software. The samples
were secured to aluminium stubs with Leit-C carbon
cement and coated with carbon (Edwards 306 high vacuum
carbon evaporation) before SEM/EDS analysis. The ele-
mental distribution on the surface of the strips was investi-
gated using EDS while surface analysis to characterize the
morphology of strips was evaluated using SEM at nominal
magniﬁcations of 9500 and 91000. The accelerating volt-
age of the incident electron beam was set at 10 kV to mini-
mize beam damage to the sample while maintaining
adequate excitation. The raw X-ray maps were processed
for background removal to give net counts for each of the
analytical X-ray lines. Chlorine (Cl) atoms were taken as a
marker atom since it was only present in the structure of
the drug.
Thermal analysis
The physical form of the pure drug, physical mixtures and
extruded strips was examined using a Mettler-Toledo 823e
(Greifensee, Switzerland) differential scanning calorimeter.
Samples were prepared in sealed aluminium pans (2–5 mg)
with a pierced lid. The samples were heated at 10 °C/min
under nitrogen atmosphere in a temperature range between
0 and 250 °C.
Transmission X-ray diffraction analysis
A D8 Advantage X-ray diffractometer (Bruker AXS GmbH,
Karlsure, Germany) was employed to study the crystallinity
of KTZ on the extruded strips. The transmission diffrac-
tograms were acquired with Diffrac Plus XRD Commander
over a start to end diffraction 2h angle of 2–40°, scan speed
of 0.2 s and step size of 0.02 and a counting time of 0.4 s
per step; 176 channels active on the PSD making a total
counting time of 70.4 s per step. The operating conditions
were 40 kV and 40 mA with Cu Ka radiation. All acquired
data were processed with EVA software for bulk substances
and the extruded strips.
In-vitro drug release studies
In-vitro dissolution study of pure drug and extrudates was
carried out by using a Varian 705 DS dissolution paddle
apparatus (Varian Inc. North Carolina, US) at 100 rpm
and 37  0.5 °C. The dissolution medium pH was main-
tained at 6.8 using 900 ml of 0.2 M potassium dihydrogen
phosphate buffer (adjusted with 2.0 M NaOH solution) for
2 h. The temperature was equilibrated to 37  0.5 °C. At
predetermined time intervals, samples were withdrawn for
HPLC assay and replaced with fresh dissolution medium.
All dissolution studies were performed in triplicate.
HPLC analysis
The release of KTZ from the prepared extrudates (strips)
was determined by HPLC. An Agilent Technologies system
equipped with a Sperisorb S50DS1 (150 mm 9
4.6 mm 9 5 lm) column at 230 nm was used for the KTZ
© 2016 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology, ** (2016), pp. **–** 3
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HPLC assay. The mobile phase consisted of methanol/wa-
ter/triethyl amine (80: 20: 0.2, v/v/v). The ﬂow rate was
1.5 ml/min and the retention time of KTZ was about
2 min. The KTZ calibration curve (R2 = 0.999), at concen-
trations varying from 5 to 100 lg/ml, was used to evaluate
all the samples with 20 ll injection volume.
Statistical analysis
All statistical analyses of the data for swelling studies were
conducted using Microsoft Excel 2013 (USA). Dissolution
proﬁles were investigated for the signiﬁcance of difference
among the distribution of the independent variables using
a nonparametric statistical test of signiﬁcance – Kruskal–
Wallis test (Vassarstats, Poughkeepsie, NY USA).
Results and Discussion
Drug/polymer miscibility
The prediction of drug/polymers miscibility prior to the
selection of appropriate hydrophilic strips forming polymer
in all extruded formulations was successfully determined by
the solubility parameters (d) using the Van Krevelen/Hofty-
zer Equation (1).[17,20] Generally, the drug/polymers misci-
bility is achieved via the optimized stability between the
energy released by inter molecular interactions and intra
molecular interactions within the components.[21] The the-
oretical approach derived from the solubility parameter
suggests that compounds with similar d values are likely to
be miscible. The reason is that the energy of mixing from
intramolecular interactions with particular components is
then balanced with the energy of mixing from intermolecu-
lar interactions between the components (drug/polymer).
Therefore, it has been demonstrated that compounds with
Dd < 7 MPa1/2 are likely to be miscible and compounds
with Dd > 10 MPa1/2 are likely to be immiscible.[21,22]
The calculated solubility parameter of KTZ, HPMC and
SOL was 20.60, 24.61 and 19.41 MPa1/2, respectively. The
difference between the calculated solubility parameters of
the polymers and the drug indicates that KTZ is likely to
form solid dispersions with both polymers HPMC and
SOL. Using the Van Krevelen/Hoftyzer equation, the Dd
values for KTZ/HPMC and KTZ/SOL were 4.01 and
1.19 MPa1/2, respectively.
Continuous manufacturing of strips via HME
As shown in Figure 1, extrusion processing followed by
downstream equipment was optimized to obtain the extru-
dates in the form of whitish strips. For this study, a spe-
cially designed die was coupled with the extruder to
produce strips with approximately 0.5-mm thickness. The
extruded strips were directed onto a compressed air facili-
tated conveyor belt and accurately cut into small pieces to
produce strips of 1 cm 9 5 cm size. During the process
optimization of KTZ-loaded strips, a range of temperature
proﬁles varying from 120 to 140 °C feed rates and screw
speeds were evaluated as they play a key role in the product
development. The process was eventually optimized to pro-
vide a throughput of 1Kg/h. SOL was chosen due to its abil-
ity to enhance the dissolution rates of poorly water-soluble
drugs in HME processing while HPMC possesses very good
adhesive properties.[14] In terms of the extrusion processi-
bility, HPMC ﬁlms appeared to be easier to handle com-
pared to those of SOL due to the brittle nature of the latter.
Therefore, the best two formulations (F1 and F2) with
HPMC were taken for further characterizations. The pres-
ence of MAS in the strip formulations facilitated smooth
extrusion and subsequently cutting of the strips.
Figure 1 (i) Continuous manufacturing process of oral KTZ strips via advanced HME process and (ii) digital photographs of representative
extruded KTZ strips. KTZ, Ketoconazole; HME, Hot-melt extrusion.
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Swelling capacity
The hydration (swelling) proﬁles of the extruded ﬁlms are
presented in Table 2. The various formulations showed dif-
ferences in their swelling proﬁles with the blank (no drug)
HPMC and SOL strips showing slow initial hydration and
gradual swelling over the measurement period. SOL-con-
taining strips generally showed signiﬁcantly higher swelling
(P < 0.05) capacity than HPMC.
However, the KTZ-containing strips showed very rapid
hydration and swelling in the ﬁrst 20 min, signiﬁcantly
higher than blank strips followed by a drastic reduction
after 40 min and eventually complete ﬁlm disintegration
occurred, suggesting it perhaps behaves as a semifast disin-
tegrating system. This is due largely to the presence of
MAS, which has high water afﬁnity and hence causes rapid
disintegration of the formulation. This is evidenced by the
signiﬁcantly very low swelling capacities recorded for the
control strips in the absence of MAS. Further evaluation of
the data shows that for blank formulations, peak swelling
occurred at 60 min, while the drug-loaded strips (F1 and
F2) showed peak swelling capacity in only 20 min after
which the values decreased signiﬁcantly until they
eventually disintegrated within a 60-min time period. This
indicates that in addition to MAS, the amorphous nature of
the drug present within the extruded strips contributed
towards their initial hydration characteristics and eventual
disintegration. The7 differences observed are interesting and
expected to affect the dissolution proﬁles signiﬁcantly since
initial hydration and swelling, to determine the rate of drug
release by diffusion or eventual disintegration (erosion) of
the polymer matrix.
In-vitro mucoadhesion studies
Figure 2 shows the mucoadhesion (PAF, TWA and cohe-
siveness) proﬁles of the tested formulations. The HPMC-
based formulations showed higher PAF values than the
SOL-containing strips. In contrast, the drug-loaded strips
(F1 and F2) showed signiﬁcantly (P < 0.05) higher
Table 2 Swelling profiles for the different formulations tested showing differences in hydration behaviour based on type of polymer and drug
content
Formulation
Swelling (%)
Time (min)
20 40 60 80
HPMC (Blank) 203.53  0.30 232.69  0.25 239.74  0.30 226.60  0.1
SOL (Blank) 292.73  0.25 413.94  0.33 427.27  0.30 418.79  0.2
Control 4.41  0.31 5.25  0.30 5.09  0.20 3.65  0.20
F1 509.58  0.35 395.02  0.30 Disintegrated
F2 408.70  0.30 263.35  0.20 Disintegrated
HPMC, hydroxypropyl methylcellulose; SOL, soluplus.
Figure 2 10In-vitro mucoadhesion data for the various blank and
drug-loaded formulations showing changes in mucoadhesive proper-
ties with change of polymer and drug loading content.
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mucoadhesion (PAF and TWA) values compared to the
blank strips, although the cohesiveness, which is the dis-
tance of travel before detachment, did not follow this trend,
but it was still evident that the values were generally slightly
higher for drug-loaded strips than the blank ones. In addi-
tion, there was a signiﬁcant (P < 0.05) difference in PAF
and the cohesiveness between the higher KTZ (F1)- and
lower KTZ (F2)-loaded strips while the TWA of the two
formulations (F1 and F2) was almost identical. An interest-
ing observation from the results is that F2 showed higher
PAF and lower cohesiveness than F1 (opposite effect) even
though both had similar TWA values. This is because the
TWA is a function of both PAF and the distance travelled
(area under the force–distance plot), and therefore, their
(PAF and cohesiveness) combined effect (TWA) was simi-
lar for both F1 and F2.
The above observations could be explained by the swel-
ling capacity (Table 2), which plays an important role
during the initial stages of mucoadhesion. In a typical
mucoadhesion process, the polymer hydrates initially,
which increases chain mobility. This subsequently allows
the chains to interpenetrate into mucin present on the
model mucosal surface and eventually form strong inter-
actions via either hydrogen or covalent bonding. There-
fore, the drug-loaded strips, which showed rapid
hydration and subsequent disintegration (Table 2), will
have exhibited a stronger initial interaction with the
model mucosal surface. Further, because the volume of
moisture available was not high on the gelatine surface
(compared to oral mucosa washed with saliva), it had a
longer time to bond more strongly with the model muco-
sal surface. However, due to its high apparent water afﬁn-
ity at lower drug loading (F2), the initial strong bonds
are disrupted as the strips disintegrated to form slippery
mucilage and therefore the cohesiveness will be expected
to decrease.
Figure 3 11Scanning electron microscopy images of Ketoconazole-loaded oral strips (F1).
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Further, the control formulation (absence of MAS)
showed higher PAF and TWA values than all the other
formulations but lower cohesiveness than F1 and F2.
Again, this could relate to the swelling and hydration
behaviour as noted above, where the control strips
showed very minimal hydration. This minimal hydration
is enough to enable interaction with mucin but because
the control strips did not hydrate to the same extent as
F1 and F2, it will not have had the chance to travel over
a longer distance before ﬁnal detachment from the
model mucosal substrate. Overall, it appears that the
main factors affecting the mucoadhesive properties were
the drug content and the presence or absence of MAS
in the formulations. Both the drug and MAS are not
mucoadhesive and generally appear as brittle substances
in formulations. The results also suggest that drug-
loaded strips will hydrate rapidly enough to allow drug
diffusion out of the swollen gel but remain on the oral
mucosa long enough to allow some level of absorption
across the permeable oral (buccal and sublingual)
mucosa.
SEM/EDS analysis
The surface morphology was examined by SEM using both
secondary and backscattered electron imaging for both the
drug and extruded strips (HPMC-based). The strips con-
taining HPMC polymer and excipients exhibited no drug
crystals on the extrudate surface with KTZ (Figure 3). All
extruded strips showed smooth surface. SEM/EDS was used
to determine the elemental composition and distribu-
tion[23] of KTZ strips. As can be seen in Figure 4a, C, O,
Na, Mg, Al, Si and Cl atoms were detected on the surface of
extruded ﬁlms, which are directly related to the materials
used during the HME processing. For example, the elemen-
tal distribution of Mg, Si and Al indicates the presence of
Figure 4 12(a) Elemental analysis mapping of the extruded strips using EDS (F2) and (b) EDS mapping of the Cl atoms (marker atom) of both KTZ
and extruded strips to analyse the drug distribution on the surface of the continuously extruded strips. EDS, energy dispersive X-ray; KTZ, Keto-
conazole.
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Figure 5 Differential scanning calorimetry thermograms of (a) bulk KTZ, MAS, PEG, SRB, HPMC, NaCMC and (b) extruded strips (EXT) and physical
mixtures. KTZ, Ketoconazole; MAS, magnesium aluminometasilicate; PEG, polyethylene glycol; SRB, sorbitol; HPMC, hydroxypropyl methylcellulose.
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the synthetic amorphous MAS (Mg.AlSiO3.2H2O) in the
extruded strips. As expected, the most abundant element
was carbon (which is present in a majority of the drugs and
additives used in oral drug delivery) in both KTZ and all
polymer/excipients used in this study.
As none of the excipients/compounds, used during the
extrusion process, contain Cl atoms in their chemical struc-
tures, it was treated as a marker atom. Therefore, any pres-
ence of Cl atoms in the extruded strips would have come
from the drug itself. As can be seen in Figure 4b that pure
KTZ exhibits a homogenous distribution of Cl atoms in
EDS mapping indicated by green colour. Similarly, the dis-
tribution of KTZ on the surface of the strips was visualized
by EDS elemental mapping of Cl atoms (Figure 4b). Simi-
lar to the pure KTZ, the distribution of Cl atoms on the
surface of the continuously extruded strips was homoge-
nous. Backscatter electron images (BEI) show the sample
morphology, while the background-subtracted net-count
Cl Ka X-ray maps and overlays of the X-ray maps onto the
BEI show the homogenous distribution of Cl in the sample.
From the EDS mapping analysis, it is obvious that KTZ is
homogenously dispersed into the manufactured strips dur-
ing the extrusion processing.
Thermal analysis
Differential scanning calorimetry (DSC) was used to anal-
yse the solid state of the pure API, polymers, their physical
mixtures (PM) and active extruded strips (EXT). The over-
all ﬁndings from DSC results are summarized in Figure 5a
and 5b. The thermograms of pure KTZ showed an
endothermic transition corresponding to its melting at
150.32°C (∆H = 98.78 J/g) with an onset at 147.88 °C.
Similarly, the pure polymer showed a thermal transition via
a clear step change at 158.76 °C corresponding to the Tg of
HPMC and 59.23 °C corresponding to Tg of NaCMC,
respectively (Figure 5a). In addition, SRB and PEG exhib-
ited sharp thermal transitions due to the melting at 95.92
and 50.37 °C, respectively (Figure 5a) while amorphous
MAS showed a ﬂat line. The physical mixtures exhibited
endothermic peaks (Figure 5a) corresponding to the initial
substances at slightly shifted temperatures indicating the
drug existence in its crystalline form. In the physical mix-
tures of F1 and F2, three endothermic peaks were visible
(Figure 5b), one at 51.30 °C corresponding to the melting
peak of crystalline PEG present in the mixture followed by
the transition at 98.52 °C due to the melting of SRB. The
endothermic peak at 150.25 °C corresponds to the melting
of the crystalline KTZ. Furthermore, the extruded formula-
tions presented only one endothermic peak between 47.36
and 47.97 °C that was attributed to SRB. The absence of
melting endothermic KTZ peaks suggests the presence of
the drug in amorphous state.[21,24,25]
Transmission X-ray diffraction analysis
The extruded strips, including pure drug and physical mix-
tures of the same composition as well as pure compounds,
were studied by transmission X-ray diffraction analysis to
examine the crystalline state of the drug. As depicted in Fig-
ure 6a, the diffractograms of pure KTZ presented distinct
peaks at 6.75, 17.50, 19.08, 20.42, 23.79, 24.42 and 28.22 2h,
Figure 6 13XRD transmission diffractograms of (a) pure substances (MAS, SRB, HPMC, KTZ and PEG) and (b) extruded strips (F1 and F2) and bulk
KTZ. KTZ, Ketoconazole; MAS, magnesium aluminometasilicate; PEG, polyethylene glycol; SRB, sorbitol; HPMC, hydroxypropyl methylcellulose.
Figure 7 In-vitro dissolution analysis of ketoconazole and extruded
strips in phosphate buffer pH 6.8 (n = 3, 37  0.5 °C; 100 rpm).
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while PEG showed two distinct peaks with relatively high
intensity at 19.25 and 22.31 2h. Similarly, pure SRB showed
its characteristic crystalline peaks at positions ranging from
11 to 35.20 2h. Due to their amorphous nature, HPMC and
MAS showed typical amorphous halos in the diffrac-
tograms.
The physical mixture of both formulations presented
identical peaks (data not shown) at lower intensities sug-
gesting that the drug retain its crystalline properties. In the
extruded strip formulations (Figure 6b), there were two
distinct peaks that correspond to the presence of PEG;
however, no peaks due to the crystalline drug were
observed. The absence of KTZ peaks strongly suggests the
presence of amorphous API in the extruded solid disper-
sion containing oral strips.
In-vitro dissolution study
The main challenge for this study was to increase the disso-
lution rate of the poorly water-soluble KTZ (water solubil-
ity 17 lg/ml) [15] to provide a rapid release. In Figure 7, it
can be seen that extruded strips containing 20% of KTZ
(F1) provided rapid dissolution rates (cumulative release of
70% in 60 min at pH 6.8) compared to bulk KTZ that pre-
sented signiﬁcantly slower dissolution. The result was com-
plemented by previous studies reported elsewhere and is
expected given the pKa values for KTZ (2.94, 6.15).[26] This
enhancement of the dissolution can be attributed to the
formation of amorphous solid dispersions of KTZ in the
extruded strips. In addition to the hydrophilic polymers,
the presence of the inorganic MAS contributed to the
enhanced release of KTZ. It has been reported that MAS
releases silicic acid, Mg2+ and Al3+ [27,28] ions in dissolution
medium, which facilitate the dissolution rates of poorly
water-soluble drugs. The extruded strips presented similar
release patterns and the 20% KTZ-loaded formulations
provided slightly faster release rates compared to those of
15% (w/w). Application of a single-factor nonparametric
statistical test of signiﬁcance – Kruskal–Wallis test
(P > 0.05) to the results showed no signiﬁcant differences
between the release proﬁles. Nevertheless, the HME
extruded strips showed excellent release patterns that could
provide fast onset action in future clinical trials.
Conclusions
Hot-melt extrusion was successfully employed to manufac-
ture oral KTZ-loaded strips in a continuous mode. EDS
analysis revealed a homogeneous drug distribution on the
surface of the extruded strips while thermal analysis and
X-ray diffraction studies showed the presence of amor-
phous drug in the strips due to the intense mixing during
the extrusion processing. The presence of KTZ in amor-
phous state facilitated enhanced in-vitro dissolution rates at
ﬁve orders of magnitude compared to the bulk drug sub-
stance. The use of MAS also favoured smooth processing of
the extruded strips followed by rapid hydration, swelling
and eventually enhanced dissolution rates of the poorly
water-soluble ketoconazole.
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